Abstract Infrastructure for conducting neurological research in resource-limited settings (RLS) is limited. The lack of neurological and neuropsychological (NP) assessment and normative data needed for clinical interpretation impedes research and clinical care. Here, we report on ACTG 5271, which provided neurological training of clinical site personnel and collected neurocognitive normative comparison data in diverse settings. At ten sites in seven RLS countries, we provided training for NP assessments. We collected normative comparison data on HIV− participants from Brazil (n = 240), India (n = 480), Malawi (n = 481), Peru (n = 239), South Africa (480), Thailand (n = 240), and Zimbabwe (n = 240). Participants had a negative HIV test within 30 days before standardized NP exams were administered at baseline and 770 at 6 months. Participants were enrolled in eight strata, gender (female and male), education (<10 and ≥10 years), and age (<35 and ≥35 years). Of 2400 enrolled, 770 completed the 6-month follow-up. As expected, significant betweenSummary ACTG A5271 collected neurocognitive normative comparison test data in 2400 at-risk HIV seronegative participants from Brazil, India, Malawi, Peru, South Africa, Thailand, and Zimbabwe. The participants were enrolled in strata by site (ten levels), age (two levels), education (two levels), and gender (two levels). These data provide necessary normative data infrastructure for future clinical research and care in these diverse resource-limited settings. Neurovirol. (2016) 22:472-478 DOI 10.1007 country differences were evident in all the neurocognitive test scores (p < 0.0001). There was variation between the age, gender, and education strata on the neurocognitive tests. Age and education were important variables for all tests; older participants had poorer performance, and those with higher education had better performance. Women had better performance on verbal learning/memory and speed of processing tests, while men performed better on motor tests. This study provides the necessary neurocognitive normative data needed to build infrastructure for future neurological and neurocognitive studies in diverse RLS. These normative data are a muchneeded resource for both clinicians and researchers.
Introduction
Resource-poor, developing parts of the world continue to have the greatest burden of the human immunodeficiency virus type 1 (HIV-1) epidemic (Robertson et al. 2010; UNAIDS. updated June (2014) . The central and peripheral nervous systems (CNS and PNS) are directly impacted by HIV-1, likely through underlying effects of viral and immune factors (Zayyad and Spudich 2015) .
The resulting direct effects of HIV within the CNS are called HIV-associated neurocognitive disorders (HAND) (Antinori et al. 2007) , which includes the more severe form of HIV-associated dementia (HAD), the less severe but more prevalent HIV-associated minor neurocognitive disorder (MND), and asymptomatic neurocognitive impairment (ANI).
A major limitation of conducting neurocognitive research in resource-limited settings is the lack of infrastructure (Robertson et al. 2010; Robertson, Liner, and Heaton 2009 ). The lack of infrastructure also impedes clinical neurological care. There are no neuropsychological instruments commonly available in many resource-limited settings. In addition, there are no normative comparison data which are needed to provide the basis for clinical interpretation and diagnoses in almost all resource-limited settings (Robertson et al. 2009 ). Very few studies have gathered normative neurocognitive comparison data in resource-limited settings, and these have usually been small convenience samples. Perhaps, the most comprehensive study was undertaken by the World Health Organization (WHO) in the early 1990s (Maj et al. 1994) . The WHO study assessed HIV-associated cognitive impairment in 602 HIV-positive and 353 HIV-negative individuals in Bangkok, Thailand; Kinshasa, Zaire; Nairobi, Kenya; and São Paolo, Brazil, and was the first multinational study to accrue and use local normative data. Neurocognitive studies based in China (Heaton et al. 2008) , India (Ghate et al. 2015; Gupta et al. 2007) , and Brazil (de Almeida et al. 2013 ) among others have collected small HIV− neurocognitive data for individual studies using different tests and methods.
To address the lack of infrastructure and available normative data, ACTG 5271 study was designed and conducted to provide neurocognitive normative data for resource-limited settings in ten sites across seven countries.
Methods
Sites ACTG 5271, the International Neurocognitive Normative Comparison Study, enrolled from sites that participated in A C T G A 5 1 9 9 ( R o b e r t s o n , K . , K u m w e n d a , J . , Supparatpinyo, K., Jiang, J. H., Evans, S., Campbell, T. B., … Group, A. C. T 2011). The international ACTG sites that participated in A5271 were located in Rio de Janeiro, Brazil; Chennai, India; Pune, India; Blantyre, Malawi; Lilongwe, Malawi; Lima, Peru; Johannesburg, South Africa; Durban, South Africa; Chiang Mai, Thailand; and Harare, Zimbabwe. The volunteers were recruited at their local health clinic, voluntary counseling, and testing (VCT) center, or other HIV testing site aligned with the primary ACTG site.
Procedures
Human subject reviews and approvals by local and countryspecific review boards were obtained at each site prior to study initiation, and written informed consent was obtained prior to study participation. Standardized training on the administration of the neurological and neuropsychological screening examinations was conducted. Site study personnel were trained in face-to-face meetings with the study neuropsychologist and neurologists on site. Study personnel were required to pass a certification examination after the training and prior to study initiation. In addition, written manuals and DVD video training materials were provided to the sites for interim training updates. Annual recertification tests were required of all study personnel. Rigorous data monitoring at data entry through computerized range checks, with follow-up data cleaning through multiple queries and replies, was conducted throughout the duration of the study. Implausible values were queried and confirmed or corrected at intervals. Statistical analyses were completed with SAS, and multiple comparisons were not controlled for.
Participants
In order to recruit volunteers who mirror the economic, cultural, and risk factor epidemiology of the local HIV at-risk population, participants were recruited at their local health clinic, voluntary counseling and testing (VCT) center, or other HIV testing site aligned with the primary ACTG site.
Eligible participants were men and women 18 years or older who had documentation that they were HIV-1 seronegative within 30 days of study enrollment. Participants were excluded from participation in the study if they had any active severe psychiatric illness, active drug or alcohol abuse or dependence, serious illness and/or hospitalization within 14 days of study entry, or any other condition that, in the opinion of the site investigator, would compromise the person's ability to participate in the study, adhere to study requirements, or confound the analysis or interpretation of the results of the study. Participants were enrolled into each stratum until the stratum sample size limits were met. Participants were serially asked to participate in the follow-up visit on a voluntary basis, until the 6-month follow-up strata was filled.
Neuropsychological and neurological examinations
Standardized neurological and neuropsychological (NP) examinations (Hopkins Verbal Learning Test-Revised, Color trails 1 and 2, Wechsler Adult Intelligence Scale Digit Symbol subtest, Grooved pegboard, Timed gait, Semantic verbal fluency, Fingertapping, and the International HIV Dementia Scale) were administered at baseline. A subset of participants consented to return for a 24-week follow-up assessment to estimate practice effect. The neuropsychological tests chosen were from ACTG 5199 The International Neurological Study (Robertson et al. 2011; Robertson et al. 2012 ) based on prior experience in clinical trial and cohort studies in the ACTG and then augmented with additional tests to meet minimal HAND Frascati criteria while still maintaining a short battery with the least language-and culture-specific items. Details of the neurological examination have been reported (Robertson et al. 2011; Robertson et al. 2012) .
Results

Demographics
Participants were enrolled in the study beginning in February 2011, and the study was closed to all follow-up visits in October 2013. The total enrollment was 2400 participants, 770 participating in the 6-month follow-up, and with final enrollment for each site as follows: Johannesburg (n = 240) and Durban (n = 240) in South Africa; Lima, Peru (n = 239); Chiang Mai, Thailand (n = 240); Pune (n = 240) and Chennai (n = 240) in India; Lilongwe (n = 241) and Blantyre (n = 240) in Malawi; Rio de Janeiro, Brazil (n = 240); and Harare, Zimbabwe (n = 240). The accrual target was 30 participants per eight strata (gender (male/female) × age (<35 and ≥35 years) × education (<10 and≥10 years) at each site. The demographic means and standard deviations for the total sample and by country are presented in Table 1 .
There were 1200 (50 %) females and 1200 (50 %) males enrolled. The median age was 35 years (Q1 = 26, Q3 = 43), and the median educational level was 10 years (Q1 = 8, Q3 = 12). For ethnicity/race, there were 725 (30 %) Asians, 1323 (55 %) Blacks, 100 (4 %) White, 1 (0 %) American Indian, 250 (10 %) other, and 1 unknown (0 %). By country, there were 240 participants in Brazil, 480 in India, 481 in Malawi, 239 in Peru, 480 in South Africa, 240 in Thailand, and 240 in Zimbabwe.
Neuropsychological tests
The overall normative comparison neurocognitive test score means and standard deviations by stratification factors of gender, age, and education are presented in Table 2 . As expected and stratified for, there was variation in neuropsychological performance across countries. For example, the overall (mean (SD)) for verbal fluency was 16. The normative scores (means and standard deviations) for each NP test are presented for each site by gender, age, and education stratum in the supplemental tables.
Demographic differences
There was also variation between the age, gender, and education strata. Age was an important variable, and decreases in performance with increasing age were noted for HVLT-R learning (χ 2 = 83.01, p < 0. 
Discussion
This study provides the first large-scale multisite normative comparison data in diverse international resource-limited settings establishing a foundation to base future neurocognitive research and clinical studies upon. These data fill an existing limitation and need in both research and clinical neuropsychological areas (Robertson et al. 2009 ). Neuropsychological tests are used for assigning impairment ratings and for diagnoses (of HAND for example). Appropriate normative data are necessary to place these test results into context and did not exist in these settings prior to the data provided in the current study. There were substantial variations on the neurocognitive tests between countries, underscoring the need for countrybased normative data to be available to provide the appropriate context for valid interpretation. Other studies have found country differences, including one of the first neuropsychiatric studies in resource-limited settings conducted by the WHO (Maj et al. 1994) . Additional analyses found that there were differences within country between sites on the neurocognitive test results. While some of these differences are likely related to site demographic characteristics including education and age, it is likely that other issues such as cultural differences, rural vs. urban living, and other factors could account for the variance seen. It is very clear that age, education, and, to a lesser extent, gender are important variables in the variance associated with neurocognitive test differences and thus necessary to control for. The stratified sample collected here provides a foundation to build on for future studies.
The only known treatment for HAND is antiretroviral therapy (ART). We previously reported the first study on the impact of ART on neuropsychological functioning and neurological dysfunction in HIV-1-infected people in resource-limited settings (Robertson, K., Kumwenda, J., Supparatpinyo, K., Jiang, J. H., Evans, S., Campbell, T. B., … Group, A. C. T 2011). We found that effective ART in resource-limited settings improved neuropsychological and neurological functioning over time (Robertson et al. 2012) .
With appropriate normative data made available here, screening for neurocognitive impairment and diagnosing HAND would be possible in resource-limited settings. Where available, initiation of ART in those who screen positive or are diagnosed with HAND will very likely improve their longterm neurocognitive outcomes, which in turn will reduce mortality and increase both productivity and quality of life.
